RJFSA
PTCT icon

Raymond James Financial Services Advisors’s PTC Therapeutics PTCT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,083
Closed -$273K – 2845
2018
Q1 		$273K Buy
+10,083
New +$255K ﹤0.01% 2085
2016
Q1 		– Sell
-12,763
Closed -$414K – 2146
2015
Q4 		$414K Sell
12,763
-1,358
-10% -$40K ﹤0.01% 1289
2015
Q3 		$377K Buy
+14,121
New +$604K 0.01% 1163

Other funds holding PTCT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Raymond James Financial Services Advisors's PTCT Position: Q2 2018 in Review

Raymond James Financial Services Advisors sold out of PTC Therapeutics (PTCT) in Q2 2018, closing a stake of 10,083 shares — an estimated $273K sold.

Raymond James Financial Services Advisors first reported a position in PTCT in Q3 2015 and held it in 3 quarters. The position peaked at $414K in Q4 2015. 166 funds tracked by Wall St. Rank hold PTCT as of Q2 2018.

  • Raymond James Financial Services Advisors reported no remaining PTC Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,083 PTC Therapeutics shares in Q2 2018, an estimated $273K.
  • Raymond James Financial Services Advisors first reported a position in PTC Therapeutics in Q3 2015 and held it in 3 quarters.
  • Raymond James Financial Services Advisors's PTC Therapeutics position peaked at $414K in Q4 2015.
  • 166 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2018, filed 30 Jul 2018.